Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma (Nature Medicine, (2015), 21, 10, (1163-1171), 10.1038/nm.3952);Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma

Nature Medicine

Volumn 21, Issue 10, 2015, Pages 1163-1171

  Mazur, Pawel K ^a   Herner, Alexander ^b   Mello, Stephano S ^a   Wirth, Matthias ^b   Hausmann, Simone ^b   Sánchez Rivera, Francisco J ^c   Lofgren, Shane M ^a   Kuschma, Timo ^a   Hahn, Stephan A ^d   Vangala, Deepak ^e   Trajkovic Arsic, Marija ^b   Gupta, Aayush ^b   Heid, Irina ^b   Noël, Peter B ^b   Braren, Rickmer ^b   Erkan, Mert ^b,k   Kleeff, Jörg ^b   Sipos, Bence ^f   Sayles, Leanne C ^a   Heikenwalder, Mathias ^g,h   Heßmann, Elisabeth ⁱ   Ellenrieder, Volker ⁱ   Esposito, Irene ^b,l   Jacks, Tyler ^c   Bradner, James E ^j   Khatri, Purvesh ^a   Sweet Cordero, E Alejandro ^a   Attardi, Laura D ^a   Schmid, Roland M ^b,h   Schneider, Guenter ^b   Sage, Julien ^a   Siveke, Jens T ^b,h   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^j HARVARD MEDICAL SCHOOL   (United States)

^k KOÇ UNIVERSITY   (Turkey)

^l HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BROMODOMAIN AND EXTRATERMINAL FAMILY PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1C; HISTONE DEACETYLASE; MYC PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CELL DEATH; CONTROLLED STUDY; CRISPR CAS SYSTEM; DRUG POTENTIATION; ENZYME INHIBITION; EPIGENETICS; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, PANCREATIC DUCTAL; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; GENETIC EPIGENESIS;

ADENOCARCINOMA; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; PROTEINS;

EID: 84943653412     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-024-03054-y     Document Type: Erratum

References (79)

1. Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913-2921 (2014).
2. Hezel, A. F. , Kimmelman, A. C. , Stanger, B. Z. , Bardeesy, N. & Depinho, R. A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218-1249 (2006).
3. Ghaneh, P. , Costello, E. & Neoptolemos, J. P. Biology and management of pancreatic cancer. Gut 56, 1134-1152 (2007).
4. Maitra, A. & Hruban, R. H. Pancreatic cancer. Annu. Rev. Pathol. 3, 157-188 (2008).
5. Ryan, D. P. , Hong, T. S. & Bardeesy, N. Pancreatic adenocarcinoma. N. Engl. J. Med. 371, 1039-1049 (2014).
6. Collins, M. A. & Pasca di Magliano, M. Kras as a key oncogene and therapeutic target in pancreatic cancer. Frontiers Physiol. 4, 407 (2013).
7. Infante, J. R. et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur. J. Cancer 50, 2072-2081 (2014).
8. Bardeesy, N. & DePinho, R. A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2, 897-909 (2002).
9. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012).
10. Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501 (2015).
11. Bardeesy, N. et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl. Acad. Sci. USA 103, 5947-5952 (2006).
12. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
13. Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (2005).
14. Gidekel Friedlander, S. Y. et al. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 16, 379-389 (2009).
15. Morton, J. P. et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl. Acad. Sci. USA 107, 246-251 (2010).
16. Bardeesy, N. et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 20, 3130-3146 (2006).
17. Cook, N. , Jodrell, D. I. & Tuveson, D. A. Predictive in vivo animal models and translation to clinical trials. Drug Discov. Today 17, 253-260 (2012).
18. Witkiewicz, A. K. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).
19. Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 11, 726-734 (2011).
20. McCleary-Wheeler, A. L. et al. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett. 328, 212-221 (2013).
21. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011).
22. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
23. Lové n, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334 (2013).
24. Means, A. L. et al. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 132, 3767-3776 (2005).
25. Morris, J. P. , Cano, D. A. , Selkine, S. , Wang, S. C. & Hebrok, M. Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J. Clin. Invest. 120, 508-520 (2010).
26. Sahai, V. et al. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol. Cancer Ther. 13, 1907-1917 (2014).
27. Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691-1703 (2013).
28. Sherman, M. H. et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159, 80-93 (2014).
29. Ardito, C. M. et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22, 304-317 (2012).
30. Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
31. Singh, M. et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 28, 585-593 (2010).
32. Garcia, P. L. et al. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene doi:10. 1038/onc. 2015. 126 (2015).
33. Roy, N. et al. Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. Genes Dev. 29, 658-671 (2015).
34. Schleger, C. , Verbeke, C. , Hildenbrand, R. , Zentgraf, H. & Bleyl, U. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: Incidence, mechanisms, and clinical significance. Mod. Pathol. 15, 462-469 (2002).
35. Lesina, M. et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19, 456-469 (2011).
36. Fukuda, A. et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19, 441-455 (2011).
37. McAllister, F. et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25, 621-637 (2014).
38. Pylayeva-Gupta, Y. , Lee, K. E. , Hajdu, C. H. , Miller, G. & Bar-Sagi, D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836-847 (2012).
39. Sodir, N. M. et al. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 25, 907-916 (2011).
40. Rielland, M. et al. Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression. J. Clin. Invest. 124, 2125-2135 (2014)
41. Corcoran, R. B. et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 71, 5020-5029 (2011).
42. Obata, J. et al. p48 subunit of mouse PTF1 binds to RBP-Jkappa/CBF-1, the intracellular mediator of Notch signalling, and is expressed in the neural tube of early stage embryos. Genes Cells 6, 345-360 (2001).
43. Aguirre, A. J. et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112-3126 (2003).
44. Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572-575 (2010).
45. Adhikary, S. et al. Miz1 is required for early embryonic development during gastrulation. Mol. Cell. Biol. 23, 7648-7657 (2003).
46. Sato, N. , Matsubayashi, H. , Abe, T. , Fukushima, N. & Goggins, M. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin. Cancer Res. 11, 4681-4688 (2005).
47. Yan, Y. , Frisen, J. , Lee, M. H. , Massague, J. & Barbacid, M. Ablation of the CDK inhibitor p57(Kip2) results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 11, 973-983 (1997).
48. Vlachos, P. , Nyman, U. , Hajji, N. & Joseph, B. The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway. Cell Death Differ. 14, 1497-1507 (2007).
49. Sánchez-Rivera, F. J. et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 516, 428-431 (2014).
50. Guerra, C. et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291-302 (2007).
51. Guerra, C. et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19, 728-739 (2011).
52. Zhao, R. Y. et al. CDK inhibitor p57(Kip2) is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle 12, 935-943 (2013).
53. Grasso, C. S. et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med. 21, 555-559 (2015).
54. De Raedt, T. et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514, 247-251 (2014).
55. Shimamura, T. et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin. Cancer Res. 19, 6183-6192 (2013).
56. Kawaguchi, Y. et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat. Genet. 32, 128-134 (2002).
57. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418-425 (2001).
58. de Alboran, I. M. et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 14, 45-55 (2001).
59. Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133-140 (2010).
60. Mazur, P. K. et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 510, 283-287 (2014).
61. Matzuk, M. M. et al. Small-molecule inhibition of BRDT for male contraception. Cell 150, 673-684 (2012).
62. Hruban, R. H. et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res. 66, 95-106 (2006).
63. Jameson, K. L. et al. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat. Med. 19, 626-630 (2013).
64. Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827-832 (2013).
65. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).
66. Tiscornia, G. , Singer, O. & Verma, I. M. Production and purification of lentiviral vectors. Nat. Protoc. 1, 241-245 (2006).
67. Kim, M. P. et al. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat. Protoc. 4, 1670-1680 (2009).
68. José , A. et al. Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts. Oncotarget 4, 94-105 (2013).
69. Qiu, P. et al. Mutation detection using SurveyorTM nuclease. Biotechniques 36, 702-707 (2004).
70. DuPage, M. , Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064-1072 (2009).
71. Mazur, P. K. et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. USA 107, 13438-13443 (2010).
72. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011).
73. Debacq-Chainiaux, F. , Erusalimsky, J. D. , Campisi, J. & Toussaint, O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat. Protoc. 4, 1798-1806 (2009).
74. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006).
75. Chou, T. C. Drug combination sand their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446 (2010).
76. Carey, M. F. , Peterson, C. L. & Smale, S. T. Chromatin immunoprecipitation (ChIP). Cold Spring Harbor Protoc. doi:10. 1101/pdb. prot5279 (2009).
77. Khatri, P. et al. A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J. Exp. Med. 210, 2205-2221 (2013).
78. Storey, J. D. A direct approach to false discovery rates. J. R. Stat. Soc. B 64, 479-498 (2002).
79. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).